Home › Cancro al seno triplo negativo › California
Studi clinici su Cancro al seno triplo negativo nello stato di California
53 studi su Cancro al seno triplo negativo cercano partecipanti presso sedi nello stato di California.
Città nello stato di California
- Los Angeles27 studi
- San Diego13 studi
- San Francisco11 studi
- Baldwin Park10 studi
- Mountain View8 studi
- Irvine6 studi
- Santa Monica6 studi
- Newport Beach6 studi
- Orange4 studi
- Sacramento3 studi
Testo ufficiale dello studio (inglese)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- City of Hope National Medical Center, Duarte
- University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06465069The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of San Diego Moores Cancer Center, La Jolla
- UCLA Jonsson Comprehensive Cancer Center, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04585750A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- University of California - Los Angeles, Los Angeles
In reclutamentoFase 1
Età 19 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06586957Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- University of California San Diego, La Jolla
- Stanford University, Palo Alto
- UCLA Medical Center, Santa Monica
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT04981119A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- City of Hope ( Site 0097), Duarte
- City of Hope Lennar Foundation Cancer Center ( Site 0099), Irvine
- UCLA Department of Medicine - Hematology & Oncology ( Site 0047), Los Angeles
- e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06841354Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- MemorialCare Orange Coast Medical Center ( Site 9501), Fountain Valley
- Scripps Cancer Center ( Site 0052), La Jolla
- Kaiser Permanente - Oakland ( Site 0079), Oakland
- e altri 7
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06393374A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Roy and Patricia Disney Family Cancer Center ( Site 0055), Burbank
- Community Cancer Institute ( Site 0100), Clovis
- Providence Medical Foundation ( Site 0080), Fullerton
- e altri 4
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06966700A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
- Kivu Trial Site, Santa Monica
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 set 2026 · NCT07229313Intratumoral N17350 in Advanced Solid Tumors
- The Angeles Clinic and Research Institute, Los Angeles
- UCLA - Jonsson Comprehensive Cancer Center, Los Angeles
- Scripps Clinic Torrey Pines - La Jolla, San Diego
- e altri 1
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07339176Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Beverly Hills Cancer Center, Beverly Hills
- City of Hope Cancer Center, Duarte
- University of California Irvine Medical Center, Orange
- e altri 1
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 set 2026 · NCT05983432A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- City of Hope, Duarte
- Hoag Memorial Hospital Presbyterian, Irvine
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT07020117Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
- Ellison Institute of Technology (EITM), Los Angeles
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT06353997Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Alta Bates Summit Medical Center, Berkeley
- PIH Health Whittier Hospital, Downey
- Cedars-Sinai Cancer at Beverly Hills, Los Angeles
- e altri 6
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 set 2026 · NCT05633654A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 set 2026 · NCT06400472Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- PIH Health Whittier Hospital, Whittier
In reclutamentoStudio osservazionale
Età da 18 a 99 · Tutti i sessi · Aggiornato il 3 set 2026 · NCT07211178A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- City of Hope, Duarte
- UC San Diego Moores Cancer Center, La Jolla
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 ago 2026 · NCT07029399A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Community Cancer Institute, Clovis
- USC/Norris Comprehensive Cancer Center, Los Angeles
- Hoag Memorial Hospital Presbyterian, Newport Beach
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT04895709Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- USC Norris Comprehensive Cancer Center, Los Angeles
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 ago 2026 · NCT05985655Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
- Stanford University, Stanford
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 12 ago 2026 · NCT04768426SMP-3124LP in Adults With Advanced Solid Tumors
- Cedars Sinai Medical Center, Los Angeles
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 12 ago 2026 · NCT06526819A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer
- City of Hope at Arcadia, Arcadia
- City of Hope Medical Center, Duarte
- City of Hope at Seacliff, Huntington Beach
- e altri 8
In reclutamento
Età 18 e oltre · Donne · Aggiornato il 10 ago 2026 · NCT07741968A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Helios Clinical Research, Cerritos
- USC/Norris Comprehensive Cancer Center, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
- e altri 2
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 ago 2026 · NCT06926868Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer
- Cedars-Sinai Medical Center, Los Angeles
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 ago 2026 · NCT05318469Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- University of California Los Angeles Medical Center, Los Angeles
- University of California, San Diego; Moores Cancer Center, San Diego
- USOR Sansum Clinic, Santa Barbara
- e altri 1
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 ago 2026 · NCT05579366Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
- Cedars-Sinai Medical Center, Los Angeles
- Cedars-Sinai Medical Center Beverly Hills, Los Angeles
- Huntington Cancer Center, an Affiliate of CS Cancer, Pasadena
- e altri 1
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 ago 2026 · NCT07017673Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- University of California LA, Los Angeles
- Stanford University Medical Center, Palo Alto
In reclutamentoFase 1
Età da 18 a 100 · Tutti i sessi · Aggiornato il 29 lug 2026 · NCT06562192A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
- University of California Davis Comprehensive Cancer Center, Sacramento
- e altri 1
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 lug 2026 · NCT05208762A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 lug 2026 · NCT07318805Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
- Chao Family Comprehensive Cancer Center University of California, Irvine, Orange
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 lug 2026 · NCT07064018A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- UC Irvine Health-Chao Family Comprehensive Cancer Center, Orange
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
- UCLA David Geffen School of Medicine, Division of Hematology/Oncology, Santa Monica
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 giu 2026 · NCT05377996A Study of LY4175408 in Participants With Advanced Cancer
- Stanford Medicine Cancer Center, Stanford
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 giu 2026 · NCT07046923Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- City of Hope National Medical Center /ID# 276272, Duarte
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278589, Irvine
- USC Norris Comprehensive Cancer Center /ID# 279603, Los Angeles
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 giu 2026 · NCT05005403Study of XB010 in Subjects With Solid Tumors
- City of Hope Orange County Lennar Foundation Cancer Center, Irvine
- UCLA Department of Medicine - Hematology/Oncology, Los Angeles
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 giu 2026 · NCT06545331ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
- University of California, San Francisco, San Francisco
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 11 giu 2026 · NCT06224673Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
- Start Lacn, Los Angeles
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 giu 2026 · NCT07517198A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- Stanford Women's Cancer Center, Palo Alto
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 giu 2026 · NCT04300556A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
- USC / Norris Comprehensive Cancer Center, Los Angeles
In reclutamentoFase 1
Età 18 e oltre · Donne · Aggiornato il 19 mag 2026 · NCT05989828I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- University of California - Davis, Comprehensive Cancer Center, Davis
- City of Hope, Duarte
- University of California San Diego, La Jolla
- e altri 3
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 6 mag 2026 · NCT01042379Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
- University of California San Francisco, San Francisco
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 mag 2026 · NCT04434040Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
- Cedars-Sinai Medical Center, Los Angeles
In reclutamentoFase 2
Età 18 e oltre · Donne · Aggiornato il 20 apr 2026 · NCT05491226Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.